ERIS - Eris Lifesciences

Eris Lifesciences

ERIS · Pharma > Pharmaceuticals & Drugs · Chairman: Amit Indubhushan Bakshi · MD: Amit Indubhushan Bakshi · Listing date: June 30, 2017 · Employees: 3246 · Ahmedabad · http://www.eris.co.in

Stock Price vs Company Growth

0.1%

3.0%

6.9%

1.9%

21.7%

13.3%

all

9.7%

🤔 How to analyze this graph?

Last Traded Price

₹ 1,351 0.1%

1,316

1,518

Company Overview

Sales

3,230 Cr

Growth: 11.5%

Profit after Tax

644 Cr

Growth: 3.9%

Mid Cap

18,723 Cr

P/E: 28.8x

Industry P/E: 31.7x

Fundamentals

Sales (Cr)	₹ 3,230
Growth	11.5%
EBITDA	35.3%
P/S	5.8x
Dividend	0.0%
P/E	28.8x
Book Value	₹ 292
PEG Ratio	2.5x
ROE	18.1%
P/B	4.6x

Shareholding Pattern

Institutions

Emerald Investments Limited

5.51 %

Uti Flexi Cap Fund

4.25 %

Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Equity Hybrid '95 Fund

1.78 %

Franklin India Smaller Companies Fund

1.38 %

Fundsmith Emerging Equities Trust Plc

1.09 %

Promoters

Amit Indubhusan Bakshi

40.28 %

Rajendrakumar Rambhai Patel

4.37 %

Inderjeet Singh Negi

4.37 %

Kaushal Kamleshkumar Shah

3.29 %

Himanshu Jayantbhai Shah

0.37 %

Others

Rakesh Shah

11.55 %

Bhikhalal Chimanlal Shah

6.53 %

Hetal Rasiklal Shah

2.72 %

Increase Decrease No change

Company Profile Detailed

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.History and milestones2007: Incorporation of the company.

Belongs to (22 Indices) view more

Investors (53)

motilal....

hdfc.mut...

Followers (11)

haresh

nihal

rajagopa...